Skip to main content

Table 4 Comorbidities of reported patients by fibrosis stage, for patients with a current fibrosis score

From: Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database

Comorbidities

T2D

Hyperlipidemia

Hypertension

Obesity

Insulin resistance

Metabolic syndrome

CVD

Depression

Hypothyroid

CKD

Total (n = 2,312)

56%

50%

46%

42%

27%

17%

15%

11%

9%

8%

F0 (n = 189)

42%

33%

29%

32%

22%

12%

5%

9%

5%

1%

F1 (n = 576)

47%

39%

40%

30%

22%

15%

10%

10%

9%

3%

F2 (n = 843)

59%

55%

49%

42%

29%

18%

14%

11%

8%

6%

F3 (n = 486)

63%

58%

55%

56%

31%

19%

20%

13%

9%

14%

F4 (n = 218)

64%

52%

49%

56%

29%

22%

25%

21%

13%

22%

  1. Abbreviations: T2D, type 2 diabetes; CVD, cardiovascular disease; CKD, chronic kidney disease. Fibrosis stages range from none (F0) to cirrhosis (F4). Patients with unknown fibrosis stage not shown (n = 54).
  2. Source: Ipsos NASH Therapy Monitor (NASH-treating physicians in US reporting on patients seen in consultation in 2016 [n = 174] and 2017 [n = 164]; data collected online). Data © Ipsos 2022, all rights reserved